amisulpride 200 mg - Résultats de recherche

Australie - anglais - Department of Health (Therapeutic Goods Administration)

amisulpride scp amisulpride 50 mg uncoated tablet blister pack

southern cross pharma pty ltd - amisulpride, quantity: 50 mg - tablet, uncoated - excipient ingredients: sodium starch glycollate type a; lactose monohydrate; microcrystalline cellulose; magnesium stearate; hypromellose - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

amisulpride scp amisulpride 100 mg uncoated tablet blister pack

southern cross pharma pty ltd - amisulpride, quantity: 100 mg - tablet, uncoated - excipient ingredients: magnesium stearate; lactose monohydrate; sodium starch glycollate type a; hypromellose; microcrystalline cellulose - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

amisulpride scp amisulpride 400 mg uncoated tablet blister pack

southern cross pharma pty ltd - amisulpride, quantity: 400 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; magnesium stearate; sodium starch glycollate type a; microcrystalline cellulose; hypromellose - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.

Australie - anglais - Department of Health (Therapeutic Goods Administration)

apo-amisulpride

amisulpride -